An overview of drugs approved in India from 1999 through 2015

Authors

  • Vihang S. Chawan Department of Pharmacology, Topiwala National Medical College and B. Y. L. Nair Charitable Hospital, Mumbai, Maharashtra, India
  • Kalpesh V. Gawand Department of Pharmacology, Topiwala National Medical College and B. Y. L. Nair Charitable Hospital, Mumbai, Maharashtra, India
  • Abhishek M. Phatak Department of Pharmacology, Topiwala National Medical College and B. Y. L. Nair Charitable Hospital, Mumbai, Maharashtra, India
  • Sagar V. Badwane Department of Pharmacology, Topiwala National Medical College and B. Y. L. Nair Charitable Hospital, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20150375

Keywords:

Drug approval, New drugs, India, Regulations

Abstract

Background: The drug approval regulations in India have changed since 2005 with new regulations for the conduct of clinical trials from 2013 onward. The present study was planned to see the number of drugs approved by Drugs Controller General of India (DCGI) and their trend over the last 16 years in view of new regulatory guidelines.

Methods: Data obtained from website of the regulatory authority, i.e., Central Drugs Standard Control Organizationregarding DGCI approval of drugs in India from 1999 until May 2015 was noted for analysis.

Results: We identified 1716 drug approvals by the DCGI from 1999 to 2015, with a mean of 100.94±83.80 (standard deviation) approvals per year (median approvals per year: 57; range: 3-270). There is a rising trend for approval of drugs as a single agent, as well as in combination from 2004 showing a peak in 2008 with a decline from 2010 onward. Thus, very few drugs have been approved in last 3 years.

Conclusions: Thus, the present study highlights the changing scenario of drug approval, with few drugs being approved for clinical practice in the last 3 years.

Metrics

Metrics Loading ...

References

Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004;38(9):1279-86.

WHO Drug Information 2014 for 16th International Conference of Drug Regulatory Authorities (ICDRA). Volume 28, No. 3. Rio de Janeiro, Brazil: WHO Drug Information; August 2014: 24-9. Available at http://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra/16_ICDRA_Recommendations2014.pdf?ua=1. Accessed 21 May 2015.

Guidelines on Approval of Clinical Trial and New Drugs. Available at http://www.cdsco.nic.in/writereaddata/Guidance_for_New_Drug_Approval-23.07.2011.pdf. Accessed 21 May 2015.

Schedule Y. Amendment version 2005, Drugs and Cosmetics Rules, 1945. Available at http://www.dbtbiosafety.nic.in/act/schedule_y.pdf Accessed 21 May 2015.

The Central Drugs Standard Control Organization (CDSCO). Mashelkar committee report. Available at http://www.cdsco.nic.in/html/Final%20Report%20mashelkar.pdf Accessed 21 May 2015.

The International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. Available at http://www.ich.org/home.html. Accessed 21 May 2015.

Clinical trials in India: ethical concerns. Bull World Health Organ. 2008;86:581-2.

Controller General of Patents, Designs and Trade Marks (CGPDTM). Available at http://www.ipindia.nic.in/. Accessed 21 May 2015.

Central Drugs Standard Control Organization Directorate General of Health Services Ministry of Health and Family Welfare Govt. of India. Available at http://www.cdsco.nic.in/forms/list.aspx?lid=1820&Id=11.

Downloads

Published

2017-01-19

How to Cite

Chawan, V. S., Gawand, K. V., Phatak, A. M., & Badwane, S. V. (2017). An overview of drugs approved in India from 1999 through 2015. International Journal of Basic & Clinical Pharmacology, 4(4), 697–700. https://doi.org/10.18203/2319-2003.ijbcp20150375

Issue

Section

Original Research Articles